A WCI survey looking at sourcing in the life science industry

Almost everyone has a point of view about the pros and cons of sourcing pharmacovigilance (PV) activities, but what is the actual utilisation of PV sourcing in industry, and what sourcing models are global organisations implementing now, and in the near term?  This paper summarises the findings of a recent WCI survey which answers the aforementioned questions and also captures industry's experiences to date; valuable insight for organisations implementing a PV sourcing strategy.

Importantly, PV sourcing is not just about contracting with external service providers (e.g. BPOs or CROs) (outsourcing) but it is also about leveraging organisational operations owned by the sponsoring company (internal sourcing) which may be situated in low cost countries.

Currently, 70% of pharmaceutical organisations outsource at least one PV activity.  This level is expected to increase to 80% by 2012.  However, no clear pattern exists within industry of a common sourcing model dominating in the near term.

To read the findings of the survey in full, please click on the pdf link below:

PV Sourcing Strategic or Tactical imperative.pdf